Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
01. Juni 2023 08:33 ET
|
Coherus BioSciences, Inc.
– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company – – YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and...